Ac Immune Sa · NASDAQ:ACIU
Ac Immune Sa — Shareholder Meeting (November 2016)
16 slides from Ac Immune Sa's shareholder meeting presentation, Nov 15, 2016
Slide 1: Novel Therapies and Diagnostics for Neurodegenerative Diseases with Focus on Alzheimer's
www.acimmune.com 2016 AC Immune - Not to be used or reproduced without permission. NOVEL THERAPIES AND DIAGNOSTICS FOR NEURODEGENERATIVE DISEASES WITH FOCUS ON ALZHEIMER’S Annual General Meeting l November 15, 2016
Slide 2: Vision
© 2016 AC Immune. Not to be used or reproduced without permission. Annual General Meeting l November 15, 2016 2 Vision SupraAntigen TM Vaccines and antibodies specific to disease causing conformations Morphomer TM Conformation - sensitive small molecules Become a global leader in neurodegenerative d
Slide 3: AC Immune – A leader in neurodegenerative diseases
© 2016 AC Immune. Not to be used or reproduced without permission. Annual General Meeting l November 15, 2016 3 AC Immune – A leader in neurodegenerative diseases Large and growing neurodegenerative disease market driven by significant unmet medical need 1 Multiple high - profile strategic alliances
Slide 4: Alzheimer's disease: early diagnosis translates into earlier treatment
© 2016 AC Immune. Not to be used or reproduced without permission. Annual General Meeting l November 15, 2016 4 Alzheimer’s disease Early diagnosis translates into earlier treatment and better outcome Genetic diagnosis AD tomorrow AD today Prevention Disease - modifying treatment Symptomatic treatme
Slide 5: Misfolded proteins and AC Immune's intervention points
© 2016 AC Immune. Not to be used or reproduced without permission. Annual General Meeting l November 15, 2016 5 Healthy cell Recipient cell Misfolded proteins are generally recognized as leading causes of neurodegenerative diseases AC Immune’s therapies intervene at key points in the disease pathway
Slide 6: AC Immune's technology leadership
© 2016 AC Immune. Not to be used or reproduced without permission. Annual General Meeting l November 15, 2016 6 AC Immune’s technology leadership SupraAntigen TM Vaccines and antibodies specific to disease causing conformations Morphomer TM Conformation sensitive small molecules Product - focused an
Slide 7: Strategy to create value and mitigate risk
© 2016 AC Immune. Not to be used or reproduced without permission. Annual General Meeting l November 15, 2016 7 Strategy to create value and mitigate risk Note: Neuro - orphan = neurodegenerative orphan disease, PD = Parkinson’s Disease, PSP = Progressive Supranuclear Palsy, LBD = Lewy Body Dementia
Slide 8: AC Immune's robust pipeline
© 2016 AC Immune. Not to be used or reproduced without permission. Annual General Meeting l November 15, 2016 8 AC Immune’s robust pipeline Driven by our proprietary technology platforms Biologics Diagnostics Small molecules Crenezumab ( anti - Abeta antibody) AD treatment Product candidate (target)
Slide 9: Highlights and achievements 2015/2016
© 2016 AC Immune. Not to be used or reproduced without permission. Annual General Meeting l November 15, 2016 9 Highlights and achievements 2015/2016 Company ▪ Received upfront payment from Janssen deal on ACI - 35 signed in December 2014 (01/2015) ▪ Awarded grant from The Michael J. Fox Foundation
Slide 10: Highlights and achievements: Clinical stage programs
© 2016 AC Immune. Not to be used or reproduced without permission. Annual General Meeting l November 15, 2016 10 Highlights and achievements Clinical stage programs Clinical stage programs ▪ Crenezumab (1) : Commenced patient recruitment of CREAD Phase 3 clinical trial in Q1 2016 ▪ ACI - 24 in DS: I
Slide 11: Highlights and achievements: Pre-clinical stage programs
© 2016 AC Immune. Not to be used or reproduced without permission. Annual General Meeting l November 15, 2016 11 Highlights and achievements Pre - clinical stage programs ▪ Morphomer Tau (AD): Demonstrated dose - dependent reduction of pathological Tau and improvement of memory ▪ Morphomer Abeta (gl
Slide 12: Strategy for value creation
© 2016 AC Immune. Not to be used or reproduced without permission. Annual General Meeting l November 15, 2016 12 Strategy for value creation EVOLVE strategy to develop late stage assets in - house CONTINUE to leverage our dual platform technologies to efficiently advance commercially viable product
Slide 13: Financial Overview
www.acimmune.com © 2016 AC Immune. Not to be used or reproduced without permission. Financial Overview Annual General Meeting l November 15, 2016
Slide 14: Financial overview (IFRS) – year ended December 31
© 2016 AC Immune. Not to be used or reproduced without permission. Annual General Meeting l November 15, 2016 14 Financial overview (IFRS) Key financial data For the Year Ended December 31 (all figures in CHF millions excepts EPS data) 2015 2014 Change Income statement Revenues 39.1 30.3 29.1% R&D e
Slide 15: Financial overview (IFRS) – balance sheet as of December 31
© 2016 AC Immune. Not to be used or reproduced without permission. Annual General Meeting l November 15, 2016 15 Financial overview (IFRS) Key financial data As of December 31, (all figures in CHF millions) 2015 2014 Balance Sheet Cash 76.5 3.3 Accounts receivable 0.3 25.9 Total assets 79.9 30.3 Tot
Slide 16: Financial overview (IFRS) – nine months ended September 30
© 2016 AC Immune. Not to be used or reproduced without permission. Annual General Meeting l November 15, 2016 16 Financial overview (IFRS) Key financial data For the Nine Months Ended September 30, (all figures in CHF millions) 2016 2015 Change Income statement Revenues 21.8 38.8 (43.8%) R&D expense